Iranian Red Crescent Medical Journal

Published by: Kowsar

The Gene-Treatment Interaction of FTO‐rs9939609 Gene Polymorphism and Epigallocatechin-Gallate Intervention on Anthropometric Indices, Fasting Blood Sugar and Insulin Resistance/Sensitivity in Patients with Type 2 Diabetes Mellitus

Seyed Ahmad Hosseini 1 , Meysam Alipour 1 , * , Mehrnoosh Zakerkish 2 , Bahman Cheraghian 3 and Pegah Ghandil 4
Authors Information
1 Department of Nutrition, Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Department of Endocrinology and Metabolism, Diabetes Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Department of Statistics and Epidemiology, Faculty of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Department of Medical Genetics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Article information
  • Iranian Red Crescent Medical Journal: December 31, 2018, 20 (12); e82228
  • Published Online: December 18, 2018
  • Article Type: Research Article
  • Received: July 16, 2018
  • Revised: October 6, 2018
  • Accepted: October 7, 2018
  • DOI: 10.5812/ircmj.82228

To Cite: Hosseini S A, Alipour M, Zakerkish M, Cheraghian B, Ghandil P. The Gene-Treatment Interaction of FTO‐rs9939609 Gene Polymorphism and Epigallocatechin-Gallate Intervention on Anthropometric Indices, Fasting Blood Sugar and Insulin Resistance/Sensitivity in Patients with Type 2 Diabetes Mellitus, Iran Red Crescent Med J. 2018 ; 20(12):e82228. doi: 10.5812/ircmj.82228.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50. doi: 10.1016/j.diabres.2017.03.024. [PubMed: 28437734].
  • 2. Lois K, Kumar S. Obesity and diabetes. Endocrinol Nutr. 2009;56S4:38-42. doi: 10.1016/S1575-0922(09)73516-8. [PubMed: 20542226].
  • 3. Willemsen G, Ward KJ, Bell CG, Christensen K, Bowden J, Dalgard C, et al. The concordance and heritability of type 2 diabetes in 34,166 twin pairs from international twin registers: The Discordant Twin (DISCOTWIN) Consortium. Twin Res Hum Genet. 2015;18(6):762-71. doi: 10.1017/thg.2015.83. [PubMed: 26678054].
  • 4. Ashtary-Larky D, Ghanavati M, Lamuchi-Deli N, Payami SA, Alavi-Rad S, Boustaninejad M, et al. Rapid weight loss vs. slow weight loss: Which is more effective on body composition and metabolic risk factors? Int J Endocrinol Metab. 2017;15(3). e13249. doi: 10.5812/ijem.13249. [PubMed: 29201070]. [PubMed Central: PMC5702468].
  • 5. Ortega A, Berna G, Rojas A, Martin F, Soria B. Gene-diet interactions in type 2 diabetes: The chicken and egg debate. Int J Mol Sci. 2017;18(6). doi: 10.3390/ijms18061188. [PubMed: 28574454]. [PubMed Central: PMC5486011].
  • 6. Xi B, Takeuchi F, Meirhaeghe A, Kato N, Chambers JC, Morris AP, et al. Associations of genetic variants in/near body mass index-associated genes with type 2 diabetes: A systematic meta-analysis. Clin Endocrinol (Oxf). 2014;81(5):702-10. doi: 10.1111/cen.12428. [PubMed: 24528214]. [PubMed Central: PMC5568704].
  • 7. Saber-Ayad M, Manzoor S, El Serafi A, Mahmoud I, Hammoudeh S, Rani A, et al. The FTO rs9939609 "A" allele is associated with impaired fasting glucose and insulin resistance in Emirati population. Gene. 2019;681:93-8. doi: 10.1016/j.gene.2018.09.053. [PubMed: 30273662].
  • 8. Zhang X, Qi Q, Zhang C, Smith SR, Hu FB, Sacks FM, et al. FTO genotype and 2-year change in body composition and fat distribution in response to weight-loss diets: The POUNDS LOST Trial. Diabetes. 2012;61(11):3005-11. doi: 10.2337/db11-1799. [PubMed: 22891219]. [PubMed Central: PMC3478519].
  • 9. Nascimento GA, Leite N, Furtado-Alle L, Teixeira MD, Souza RLR, Milano GE, et al. FTO rs9939609 does not interact with physical exercise but influences basal insulin metabolism in Brazilian overweight and obese adolescents. J Obes. 2018;2018:3134026.
  • 10. Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, Aston CE, et al. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr. 2010;29(1):31-40. [PubMed: 20595643].
  • 11. Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, Chou P. Effect of green tea extract on obese women: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2008;27(3):363-70. doi: 10.1016/j.clnu.2008.03.007. [PubMed: 18468736].
  • 12. Liu HW, Chan YC, Wang MF, Wei CC, Chang SJ. Dietary (-)-epigallocatechin-3-gallate supplementation counteracts aging-associated skeletal muscle insulin resistance and fatty liver in senescence-accelerated mouse. J Agric Food Chem. 2015;63(38):8407-17. doi: 10.1021/acs.jafc.5b02501. [PubMed: 26152236].
  • 13. Kaneko YK, Takii M, Kojima Y, Yokosawa H, Ishikawa T. Structure-dependent inhibitory effects of green tea catechins on insulin secretion from pancreatic beta-cells. Biol Pharm Bull. 2015;38(3):476-81. doi: 10.1248/bpb.b14-00789. [PubMed: 25757931].
  • 14. Liu CY, Huang CJ, Huang LH, Chen IJ, Chiu JP, Hsu CH. Effects of green tea extract on insulin resistance and glucagon-like peptide 1 in patients with type 2 diabetes and lipid abnormalities: A randomized, double-blinded, and placebo-controlled trial. PLoS One. 2014;9(3). e91163. doi: 10.1371/journal.pone.0091163. [PubMed: 24614112]. [PubMed Central: PMC3948786].
  • 15. Ehrampoush E, Arasteh P, Homayounfar R, Cheraghpour M, Alipour M, Naghizadeh MM, et al. New anthropometric indices or old ones: Which is the better predictor of body fat? Diabetes Metab Syndr. 2017;11(4):257-63. doi: 10.1016/j.dsx.2016.08.027. [PubMed: 27578617].
  • 16. de Luis DA, Aller R, Izaola O, de la Fuente B, Conde R, Sagrado MG, et al. Evaluation of weight loss and adipocytokines levels after two hypocaloric diets with different macronutrient distribution in obese subjects with rs9939609 gene variant. Diabetes Metab Res Rev. 2012;28(8):663-8. doi: 10.1002/dmrr.2323. [PubMed: 22865603].
  • 17. Zou ZC, J Mao L, Shi YY, Chen JH, Wang LS, Cai W. Effect of exercise combined with dietary intervention on obese children and adolescents associated with the FTO rs9939609 polymorphism. Eur Rev Med Pharmacol Sci. 2015;19(23):4569-75. doi: 10.2337/db11-1799. [PubMed: 26698254].
  • 18. Livingstone KM, Celis-Morales C, Papandonatos GD, Erar B, Florez JC, Jablonski KA, et al. FTO genotype and weight loss: Systematic review and meta-analysis of 9563 individual participant data from eight randomised controlled trials. BMJ. 2016;354. i4707. doi: 10.1136/bmj.i4707. [PubMed: 27650503]. [PubMed Central: PMC6168036].
  • 19. Most J, Timmers S, Warnke I, Jocken JW, van Boekschoten M, de Groot P, et al. Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: A randomized controlled trial. Am J Clin Nutr. 2016;104(1):215-27. doi: 10.3945/ajcn.115.122937. [PubMed: 27194304].
  • 20. Toolsee NA, Aruoma OI, Gunness TK, Kowlessur S, Dambala V, Murad F, et al. Effectiveness of green tea in a randomized human cohort: Relevance to diabetes and its complications. Biomed Res Int. 2013;2013:412379. doi: 10.1155/2013/412379. [PubMed: 24102055]. [PubMed Central: PMC3786468].
  • 21. Liu K, Zhou R, Wang B, Chen K, Shi LY, Zhu JD, et al. Effect of green tea on glucose control and insulin sensitivity: A meta-analysis of 17 randomized controlled trials. Am J Clin Nutr. 2013;98(2):340-8. doi: 10.3945/ajcn.112.052746. [PubMed: 23803878].
  • 22. Hsu CH, Liao YL, Lin SC, Tsai TH, Huang CJ, Chou P. Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial. Altern Med Rev. 2011;16(2):157-63. doi: 10.1089/acm.2009.0188. [PubMed: 21649457].
  • 23. InterAct C, van Woudenbergh GJ, Kuijsten A, Drogan D, van der A DL, Romaguera D, et al. Tea consumption and incidence of type 2 diabetes in Europe: The EPIC-InterAct case-cohort study. PLoS One. 2012;7(5). e36910. doi: 10.1371/journal.pone.0036910. [PubMed: 22666334]. [PubMed Central: PMC3364250].
  • 24. Phung OJ, Baker WL, Matthews LJ, Lanosa M, Thorne A, Coleman CI. Effect of green tea catechins with or without caffeine on anthropometric measures: A systematic review and meta-analysis. Am J Clin Nutr. 2010;91(1):73-81. doi: 10.3945/ajcn.2009.28157. [PubMed: 19906797].
  • 25. Quinhoneiro DCG, Nicoletti CF, Pinhel MAS, Noronha NY, Braga CBM, Oliveira BAP, et al. Green tea supplementation upregulates uncoupling protein 3 expression in severe obese women adipose tissue but does not promote weight loss. Int J Food Sci Nutr. 2018;69(8):995-1002. doi: 10.1080/09637486.2018.1442819. [PubMed: 29482377].
  • 26. Chen IJ, Liu CY, Chiu JP, Hsu CH. Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2016;35(3):592-9. doi: 10.1016/j.clnu.2015.05.003. [PubMed: 26093535].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments